These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 21572154

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
    Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group.
    Arthritis Rheum; 2003 Aug; 48(8):2122-7. PubMed ID: 12905464
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
    Isaacs JD.
    Expert Opin Biol Ther; 2009 Dec; 9(12):1463-75. PubMed ID: 19916731
    [Abstract] [Full Text] [Related]

  • 25. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data.
    Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D.
    Pharmacoepidemiol Drug Saf; 2011 Feb; 20(2):119-30. PubMed ID: 21254282
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.
    Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, Sundström C, Bertilsson L, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Klareskog L, Feltelius N.
    Ann Rheum Dis; 2005 Oct; 64(10):1414-20. PubMed ID: 15843454
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy.
    Wolfe F, Michaud K.
    Am J Med; 2004 Mar 01; 116(5):305-11. PubMed ID: 14984815
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Does safety make a difference in selecting the right TNF antagonist?
    Fleischmann R, Yocum D.
    Arthritis Res Ther; 2004 Mar 01; 6 Suppl 2(Suppl 2):S12-8. PubMed ID: 15228616
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses.
    Chen Y, Sun J, Yang Y, Huang Y, Liu G.
    Clin Rheumatol; 2016 Jan 01; 35(1):1-18. PubMed ID: 26573205
    [Abstract] [Full Text] [Related]

  • 38. [Risk of infection through use of selective immunomodulating drugs for rheumatoid arthritis].
    Harboe E, Damås JK, Omdal R, Frøland SS, Sjursen H.
    Tidsskr Nor Laegeforen; 2012 Sep 04; 132(16):1867-71. PubMed ID: 22986971
    [Abstract] [Full Text] [Related]

  • 39. Observational studies of infections in rheumatoid arthritis: a metaanalysis of tumor necrosis factor antagonists.
    Bernatsky S, Habel Y, Rahme E.
    J Rheumatol; 2010 May 04; 37(5):928-31. PubMed ID: 20360181
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.